ASCO 2024 | KEYNOTE-361: ctDNA as a biomarker in advanced urothelial carcinoma
Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, provides an overview of a retrospective analysis from the Phase III KEYNOTE-361 trial (NCT02853305), investigating the prognostic value of circulating tumor DNA (ctDNA) in advanced urothelial carcinoma (UC) treated with pembrolizumab monotherapy versus chemotherapy. Lower baseline ctDNA levels correlated with improved outcomes in patients receiving pembrolizumab. Distinct ctDNA response patterns were observed, with stronger associations between ctDNA reductions and clinical outcomes seen in the pembrolizumab arm. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses – AstraZeneca; Ipsen; MSD; Pfizer; Roche
